Real-time Estimate
Cboe BZX
03:56:33 2024-05-07 pm EDT
|
5-day change
|
1st Jan Change
|
13.16
USD
|
-9.86%
|
|
-3.86%
|
+40.38%
|
Fiscal Period: September |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
1,182
|
918.9
|
1,148
|
1,075
|
235.2
|
308.9
|
-
|
-
|
Enterprise Value (EV)
1 |
848.9
|
918.9
|
1,148
|
1,075
|
235.2
|
308.9
|
308.9
|
308.9
|
P/E ratio
|
27.2
x
|
-25.3
x
|
-14.5
x
|
-8.78
x
|
-1.75
x
|
-2.52
x
|
-3.08
x
|
-3.48
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
5.76
x
|
7.5
x
|
11.8
x
|
12.5
x
|
2.97
x
|
4.39
x
|
4.24
x
|
4.4
x
|
EV / Revenue
|
5.76
x
|
7.5
x
|
11.8
x
|
12.5
x
|
2.97
x
|
4.39
x
|
4.24
x
|
4.4
x
|
EV / EBITDA
|
20
x
|
-49.9
x
|
-13.5
x
|
-11.4
x
|
-2.21
x
|
-2.64
x
|
-2.39
x
|
6.18
x
|
EV / FCF
|
17.9
x
|
163
x
|
-16.2
x
|
-12.4
x
|
-2.1
x
|
-3.36
x
|
-2.46
x
|
-1.63
x
|
FCF Yield
|
5.58%
|
0.61%
|
-6.16%
|
-8.08%
|
-47.7%
|
-29.8%
|
-40.6%
|
-61.5%
|
Price to Book
|
2.56
x
|
2
x
|
2.88
x
|
3.33
x
|
1.09
x
|
1.72
x
|
1.68
x
|
2.12
x
|
Nbr of stocks (in thousands)
|
19,682
|
20,072
|
20,215
|
20,725
|
21,055
|
21,156
|
-
|
-
|
Reference price
2 |
60.08
|
45.78
|
56.81
|
51.87
|
11.17
|
14.60
|
14.60
|
14.60
|
Announcement Date
|
11/21/19
|
11/23/20
|
11/22/21
|
11/21/22
|
11/20/23
|
-
|
-
|
-
|
Fiscal Period: September |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
205.2
|
122.5
|
97.07
|
86.16
|
79.2
|
70.34
|
72.77
|
70.27
|
EBITDA
1 |
59.22
|
-18.42
|
-85.25
|
-93.9
|
-106.6
|
-117
|
-129
|
50
|
EBIT
1 |
36.74
|
-41.64
|
-109.6
|
-123.8
|
-137.2
|
-124.7
|
-110.9
|
-125.1
|
Operating Margin
|
17.9%
|
-34%
|
-112.88%
|
-143.74%
|
-173.23%
|
-177.33%
|
-152.43%
|
-178.08%
|
Earnings before Tax (EBT)
1 |
45.56
|
-35.02
|
-107.6
|
-122.2
|
-131
|
-138.5
|
-109.6
|
-113.2
|
Net income
1 |
46.38
|
-36.17
|
-79
|
-121.8
|
-133.8
|
-125.4
|
-112.7
|
-121.1
|
Net margin
|
22.6%
|
-29.53%
|
-81.38%
|
-141.31%
|
-168.95%
|
-178.29%
|
-154.95%
|
-172.29%
|
EPS
2 |
2.210
|
-1.810
|
-3.920
|
-5.910
|
-6.380
|
-5.785
|
-4.746
|
-4.197
|
Free Cash Flow
1 |
66
|
5.643
|
-70.75
|
-86.91
|
-112.2
|
-92
|
-125.5
|
-190
|
FCF margin
|
32.16%
|
4.61%
|
-72.88%
|
-100.87%
|
-141.67%
|
-130.79%
|
-172.47%
|
-270.4%
|
FCF Conversion (EBITDA)
|
111.45%
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
142.3%
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
11/21/19
|
11/23/20
|
11/22/21
|
11/21/22
|
11/20/23
|
-
|
-
|
-
|
Fiscal Period: September |
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
2025 Q2
|
---|
Net sales
1 |
23.58
|
27.65
|
18.72
|
19.48
|
20.32
|
23.58
|
17.8
|
18.89
|
18.93
|
18
|
17.05
|
18.23
|
17.02
|
19.9
|
15.46
|
EBITDA
1 |
-27.57
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-32
|
-
|
-
|
-
|
-
|
EBIT
1 |
-33.73
|
-30.41
|
-33.85
|
-32.54
|
-27.05
|
-30.01
|
-39.45
|
-36.71
|
-31.03
|
-34.89
|
-32.77
|
-33.13
|
-30.66
|
-31.32
|
-34.76
|
Operating Margin
|
-143.06%
|
-109.99%
|
-180.85%
|
-167.05%
|
-133.13%
|
-127.25%
|
-221.7%
|
-194.33%
|
-163.9%
|
-193.78%
|
-192.13%
|
-181.77%
|
-180.14%
|
-157.41%
|
-224.73%
|
Earnings before Tax (EBT)
1 |
-33.39
|
-30.15
|
-33.59
|
-32.15
|
-26.33
|
-29.02
|
-37.61
|
-34.84
|
-29.52
|
-34.03
|
-31.52
|
-31.73
|
-29.45
|
-32.94
|
-33.31
|
Net income
1 |
-24.6
|
-30.12
|
-33.59
|
-31.7
|
-26.35
|
-28.99
|
-37.66
|
-39.06
|
-28.11
|
-33.41
|
-31.16
|
-30.01
|
-28.59
|
-28.76
|
-32.95
|
Net margin
|
-104.34%
|
-108.92%
|
-179.48%
|
-162.74%
|
-129.68%
|
-122.9%
|
-211.62%
|
-206.78%
|
-148.46%
|
-185.56%
|
-182.7%
|
-164.64%
|
-168%
|
-144.52%
|
-213.04%
|
EPS
2 |
-1.220
|
-1.480
|
-1.630
|
-1.530
|
-1.270
|
-1.390
|
-1.790
|
-1.860
|
-1.330
|
-1.580
|
-1.470
|
-1.468
|
-1.307
|
-1.400
|
-1.560
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
11/22/21
|
2/8/22
|
5/9/22
|
8/8/22
|
11/21/22
|
2/7/23
|
5/8/23
|
8/7/23
|
11/20/23
|
2/7/24
|
5/6/24
|
-
|
-
|
-
|
-
|
Fiscal Period: September |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
|
334
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
66
|
5.64
|
-70.7
|
-86.9
|
-112
|
-92
|
-126
|
-190
|
ROE (net income / shareholders' equity)
|
10.8%
|
-7.88%
|
-18.5%
|
-33.8%
|
-49.7%
|
-58.9%
|
-61.9%
|
-63.7%
|
ROA (Net income/ Total Assets)
|
10.3%
|
-7.41%
|
-17.1%
|
-29.9%
|
-31.9%
|
-29.2%
|
-37.2%
|
-45.6%
|
Assets
1 |
452
|
488
|
462.5
|
407.1
|
418.8
|
429.6
|
303.2
|
265.7
|
Book Value Per Share
2 |
23.50
|
22.80
|
19.70
|
15.60
|
10.30
|
8.500
|
8.700
|
6.880
|
Cash Flow per Share
|
3.410
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex
1 |
5.42
|
1.45
|
0.75
|
2.13
|
9.06
|
9
|
9
|
-
|
Capex / Sales
|
2.64%
|
1.18%
|
0.77%
|
2.47%
|
11.44%
|
12.8%
|
12.37%
|
-
|
Announcement Date
|
11/21/19
|
11/23/20
|
11/22/21
|
11/21/22
|
11/20/23
|
-
|
-
|
-
|
Last Close Price
14.6
USD Average target price
20.5
USD Spread / Average Target +40.41% Consensus |
1st Jan change
|
Capi.
|
---|
| +40.38% | 309M | | +21.78% | 46.81B | | -0.87% | 41.37B | | +47.07% | 41.29B | | -3.52% | 28.87B | | +11.39% | 26.06B | | -19.07% | 19.13B | | +32.17% | 12.39B | | +0.08% | 12.08B | | +0.26% | 11.96B |
Other Biotechnology & Medical Research
|